Dr. Vinay Prasad is out at the Food and Drug Administration for the second and hopefully last time within the past 12 months. The controversial drug regulator had placed multiple stumbling blocks befo ...

Joining me on today’s call are Sean Nolan, Taysha Gene Therapies, Inc.'s Chief Executive Officer; Sukumar Nagendran, ...

Hyperfine, Inc. (NASDAQ:HYPR) Q4 2025 Earnings Call Transcript March 18, 2026 Hyperfine, Inc. beats earnings expectations. Reported EPS is $-0.06276, expectations were $-0.08. Operator: Hello, and ...

Thank you, Jenny, and thank you all for joining us today. The strength of the company's stem cell science and success in ...

Investigator-initiated trials are uniquely unsuited to a patchwork of Google Drive folders, Excel worksheets, and consumer-grade software. Industry sponsors deploy full ...

British American Tobacco looks undervalued: ~12x forward P/E, 5–6% yield, strong FCF, and digital nicotine shift. Click to ...

Medical tourism can save money, but only when the planning is rigorous. From vetting clinics and pricing to infection control, recovery timing, medications, and aftercare, these are the risks ...

U.S. businesses spent $722 billion on R&D in 2023, a 4.4% increase from the prior year. Globally, corporate R&D expenditure reached almost $1.3 trillion in 2024 — a historic high. These are staggering ...

Longeveron Inc. (NASDAQ:LGVN) Q4 2025 Earnings Call Transcript March 17, 2026 Longeveron Inc. beats earnings expectations.

For anyone who has been thinking about fixing their smile, whether due to staining from years of coffee drinking, a chip that ...

After the leucovorin got public attention as a potential autism treatment, families rushed to get it. Many doctors are torn ...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2025 Earnings Call Transcript March 12, 2026 Operator: Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics, Inc. fourth quarter ...